What are the most common retatrutide side effects? Explore clinical trial data on nausea, digestive symptoms, dose-related effects, tolerability and what researchers have learned about safety.

What does the research say about retatrutide dosing? Explore Eli Lilly’s Phase 2 and Phase 3 trials, including studied doses, escalation schedules, weight loss results and side effects.

Not all fat-loss peptides work the same way. Some help control appetite, others target fat metabolism, and some are being studied for their effects on visceral fat and body composition. This guide explores Retatrutide (GLP-3), AOD-9604, Tesamorelin, Cagrilintide, MOTS-C, and other popular compounds to help you understand which peptides may work best for different fat-loss goals.

Learn how Retatrutide, often referred to as GLP-3, differs from earlier metabolic peptides and why researchers are paying close attention to its potential impact on body composition, fat mass, lean tissue, energy expenditure, and metabolic regulation.

What is the difference between GLP-1, GLP-2, and GLP-3? This comprehensive guide explains semaglutide, tirzepatide, and retatrutide, including receptor pathways, appetite signaling, energy expenditure, and why modern metabolic peptides are becoming a major focus in obesity and body composition research.

What is the difference between GLP-1, GLP-2, and GLP-3? This comprehensive guide explains semaglutide, tirzepatide, and retatrutide, including receptor pathways, appetite signaling, energy expenditure, and why modern metabolic peptides are becoming a major focus in obesity and body composition research.